文献速递糖尿病

强化风险因素管理对2型糖尿病心血管自主神经病变的影响:ACCORD试验

Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial.
PubMed 文献 · Diabetes Care · 2020-11-03

该研究基于ACCORD试验中7275例有心血管自主神经病变(CAN)评估的2型糖尿病高危患者,分析强化降糖、降压和降脂对CAN的影响。结果显示强化降糖使CAN风险降低16%(OR 0.84),强化降压降低25%(OR 0.75),非诺贝特无效。无心血管病史者从强化降糖中获益更明显。

要点

  • 强化降糖使CAN风险降低16%,获益主要见于无心血管病史者。
  • 强化降压使CAN风险降低25%,尤其对≥65岁患者效果更显著。
  • 非诺贝特对CAN无显著影响。

核心结论

  • 强化降糖和强化降压可降低2型糖尿病患者的CAN风险,非诺贝特无效。

研究设计与样本

  • ACCORD试验的事后分析,纳入7275例有CAN评估的2型糖尿病高危患者,采用广义线性混合模型分析强化干预对CAN的影响。

主要发现

  • 与标准干预相比,强化降糖使CAN风险降低16%(OR 0.84,95%CI 0.75-0.94,P=0.003)。
  • 强化降糖的获益主要见于基线无心血管疾病者(OR 0.73,95%CI 0.63-0.85,P<0.0001),有心血管疾病者无显著获益(OR 1.10,95%CI 0.91-1.34,P=0.34),交互作用P=0.001。
  • 强化降压使CAN风险降低25%(OR 0.75,95%CI 0.63-0.89,P=0.001),尤其对≥65岁患者(OR 0.66,95%CI 0.49-0.88,P=0.005),交互作用P=0.05。
  • 非诺贝特对CAN无显著影响(OR 0.91,95%CI 0.78-1.07,P=0.26)。

关键数值与推荐

  • CAN定义为心率变异性指标低于正常分布的第5百分位数。

临床怎么用

  • 对2型糖尿病高危患者,强化降糖和强化降压可能有助于预防CAN,尤其无心血管病史者和≥65岁患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The effects of preventive interventions on cardiovascular autonomic neuropathy (CAN) remain unclear. We examined the effect of intensively treating traditional risk factors for CAN, including hyperglycemia, hypertension, and dyslipidemia, in individuals with type 2 diabetes (T2D) and high cardiovascular risk participating in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. RESEARCH DESIGN AND METHODS: CAN was defined as heart rate variability indices below the fifth percentile of the normal distribution. Of 10,251 ACCORD participants, 71% (n = 7,275) had a CAN evaluation at study entry and at least once after randomization. The effects of intensive interventions on CAN were analyzed among these subjects through generalized linear mixed models. RESULTS: As compared with standard intervention, intensive glucose treatment reduced CAN risk by 16% (odds ratio [OR] 0.84, 95% CI 0.75-0.94, P = 0.003)-an effect driven by individuals without cardiovascular disease (CVD) at baseline (OR 0.73, 95% CI 0.63-0.85, P < 0.0001) rather than those with CVD (OR 1.10, 95% CI 0.91-1.34, P = 0.34) (P interaction = 0.001). Intensive blood pressure (BP) intervention decreased CAN risk by 25% (OR 0.75, 95% CI 0.63-0.89, P = 0.001), especially in patients ≥65 years old (OR 0.66, 95% CI 0.49-0.88, P = 0.005) (P interaction = 0.05). Fenofibrate did not have a significant effect on CAN (OR 0.91, 95% CI 0.78-1.07, P = 0.26). CONCLUSIONS: These data confirm a beneficial effect of intensive glycemic therapy and demonstrate, for the first time, a similar benefit of intensive BP control on CAN in T2D. A negative CVD history identifies T2D patients who especially benefit from intensive glycemic control for CAN prevention.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Tang Y, Shah H, Bueno Junior CR, et al. Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. Diabetes Care. 2020. PMID: 33144354. doi:10.2337/dc20-1842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。